SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10 ...

Know Labs’ first study including participants with diabetes and venous blood as a comparative reference demonstrates its proprietary sensor’s accuracy and medical application. SEATTLE--(BUSINESS WIRE) ...

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (OTCQB: KNWN) unveiled today a first look at its wearable UBAND™ Continuous Glucose Monitor (CGM) along with its companion iPhone App. Phil Bosua, Know Labs ...

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment ...

As it gears up to submit its noninvasive glucose monitoring technology for potential FDA clearance, Know Labs has recruited a pair of experts to its executive team to help smooth out the process. The ...

Know Labs’ work in 2023 has been focused on two core areas, both with a goal of ushering its noninvasive glucose sensor technology closer to FDA review. Not only did the company debut in June the ...

Greetings, and welcome to the Know Labs First Quarter 2024 Earnings Conference Call. Please note this conference call is being recorded. You may submit questions through the Q&A box on the webcast at ...

In a turbulent market environment, Know Labs Inc. (KNW) stock has touched a new 52-week low, dipping to $0.12. According to InvestingPro data, the company's overall financial health score is rated as ...

Know Labs, Inc. (OTC: KNWND) a leading innovator in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology provided today an update on its intellectual property portfolio to include its ...

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (KNW) (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced that it has entered into ...